Tensive Controls, Inc is a biopharmaceutical company that develops custom peptides to treat cachexia in human cancer subjects. Cachexia is a wasting disease that is common with cancer and leads to extreme weight loss, muscle atrophy, fatigue, weakness, and extreme loss of appetite. Tensive Controls has patented and developed an approach for the development of melanocortin drugs for cachexia that are free of the side-effects that have limited their utility. Hyperactivity of the brain melanocortin system is the proximate cause of most, if not all, forms of cachexia. By controlling brain melanocortin system activity, the firm's drug candidate ameliorates cachexia, with none of the cardiovascular or behavioral side-effects that have limited drug development in this field.
